Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2019 Sep 19;10:1097. doi: 10.3389/fphar.2019.01097

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2019 Hong, Ku, Kim, Kim, Seo, Shin and Ko

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

KAJD suppresses DNCB-induced atopic dermatitis-like symptoms. (A) BALB/c mice were sensitized with the sequential application of 2% and 0.2% DNCB for 2 weeks. KAJD or tacrolimus was regularly applied to the sensitized skin for an additional 2 weeks. (B) Photographs were taken at the end of the experiment to show the appearance of skin lesions (n=8). (C) Skin severity scores of AD-like skin lesions in BALB/c mice. The total score is the sum of individual scores determined based on the symptoms of erythema/hemorrhage, edema, scaling/dryness, and excoriation/erosion. (D, E) The dorsal skin thickness (D) and spleen weights (E) of BALB/c mice were measured at the end of treatment. ^### P < 0.001 compared to the vehicle group. **P < 0.01 and ***P < 0.001 compared to the DNCB-stimulated group. Vehicle, no treatment; DNCB, 2,4-dinitrochlorobenzene; TAC, tacrolimus.